Comparison
Lanreotid vs. Teduglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Research other
CAS no.
108736-35-2
197922-42-2
Molecular weight
1096.34 g/mol
3752.13 g/mol
Half-life
no data
no data
Sequence
no data
no data
Mechanism of action
Lanreotid
Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.
Teduglutid
Teduglutide activates the GLP-2 receptor, promoting growth and regeneration of small-intestinal villi, increasing nutrient and fluid absorption and thereby reducing dependence on parenteral nutrition. The glycine substitution at position 2 makes it resistant to rapid breakdown by DPP-4.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
1
2
of which in humans
1
2
Effects recorded
2
2
Open conflicts
1
0
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Lanreotid and Teduglutid?
- Lanreotid is classified as "Research other", while Teduglutid is classified as "Research other". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Teduglutid: Teduglutide is a DPP-4-resistant analog of GLP-2 (glucagon-like peptide-2). It promotes growth and function of the intestinal mucosa and is approved for treating short bowel syndrome. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Lanreotid or Teduglutid?
- The highest available evidence level is "Human RCT" for Lanreotid and "Human RCT" for Teduglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Lanreotid and Teduglutid in Germany and the United States?
- Germany: Lanreotid — Prescription, Teduglutid — Prescription. United States: Lanreotid — Prescription, Teduglutid — Prescription. These are factual summaries with source and review date on the individual pages.